TARA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Protara Therapeutics Inc (TARA) is not a strong buy for a beginner, long-term investor at this time. While the stock has significant upside potential based on analyst price targets and the promising development of TARA-002, the technical indicators, financial performance, and lack of strong proprietary trading signals suggest waiting for a more favorable entry point.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 40.128, showing no clear signal. Moving averages are converging, and the stock is trading near its support level of 5.458, with resistance at 6.299. Overall, the technical setup does not indicate a strong buy opportunity.
Analyst ratings are highly positive, with JPMorgan and Piper Sandler initiating coverage with Overweight ratings and price targets of $27 and $24, respectively, indicating significant upside potential. TARA-002's clinical experience and ease of use are expected to drive adoption in its target markets.
Additionally, there is no recent congress trading data or significant insider/hedge fund activity to support the stock.
In Q3 2025, revenue remained at $0 with no growth. Net income improved by 18.17% YoY but remains negative at -$13.26M. EPS dropped by 38% YoY to -0.31. Overall, the company is not yet profitable, and financials do not support a strong buy case.
Analysts are optimistic, with Overweight ratings from JPMorgan and Piper Sandler and price targets of $27 and $24, respectively. Analysts highlight the potential of TARA-002 in addressing unmet medical needs in bladder cancer and lymphatic malformations.
